Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX^™

Bibliography

• Brissenden JE, Ullrich A, Francke U. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 1984;310:781-4
   PubMed Web of Science ®Google Scholar
• Tricoli JV, Rall LB, Scott J, Bell GI, Shows TB. Localization of insulin-like growth factor genes to human chromosomes 11 and 12. Nature 1984;310:784-6
   PubMed Web of Science ®Google Scholar
• Rinderknecht E, Humbel RE. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci USA 1976;73:2365-9
   PubMed Web of Science ®Google Scholar
• Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769-76
   PubMed Web of Science ®Google Scholar
• Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993;290:419-26
   PubMed Web of Science ®Google Scholar
• Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988;81:976-81
   PubMed Web of Science ®Google Scholar
• Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982;257:5038-45
   PubMed Web of Science ®Google Scholar
• Steele-Perkins G, Turner J, Edman JC, et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988;263:11486-92
   PubMed Web of Science ®Google Scholar
• Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-12
   PubMed Web of Science ®Google Scholar
• Siddle K, Urso B, Niesler CA, et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001;29:513-25
   PubMed Web of Science ®Google Scholar
• Schwander JC, Hauri C, Zapf J, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 1983;113:297-305
   PubMed Web of Science ®Google Scholar
• Baxter RC, Martin JL. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 1989;86:6898-902
   PubMed Web of Science ®Google Scholar
• D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984;81:935-9
   PubMed Web of Science ®Google Scholar
• Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82
   PubMed Web of Science ®Google Scholar
• Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324-9
   PubMed Web of Science ®Google Scholar
• Dunger D, Yuen K, Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004;62 Suppl 1:101-7
   PubMed Web of Science ®Google Scholar
• Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR. Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci USA 2000;97:6868-73
   PubMed Web of Science ®Google Scholar
• Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002;110:771-81
   PubMed Web of Science ®Google Scholar
• Laron Z, Blum W, Chatelain P, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993;122:241
   PubMed Web of Science ®Google Scholar
• Walenkamp MJ, Karperien M, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-64
   PubMed Web of Science ®Google Scholar
• Walenkamp MJ, van der Kamp HJ, Pereira AM, et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab 2006;91:3062-70
   PubMed Web of Science ®Google Scholar
• Okubo Y, Siddle K, Firth H, et al. Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. J Clin Endocrinol Metab 2003;88:5981-8
   PubMed Web of Science ®Google Scholar
• Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987;317:137-40
   PubMed Web of Science ®Google Scholar
• Russell-Jones DL, Bates AT, Umpleby AM, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 1995;25:403-11
   PubMed Web of Science ®Google Scholar
• Frick F, Oscarsson J, Vikman-Adolfsson K, Ottosson M, Yoshida N, Eden S. Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle. Am J Physiol Endocrinol Metab 2000;278:E729-37
   PubMed Web of Science ®Google Scholar
• Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 1995;96:1722-9
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54
   PubMed Web of Science ®Google Scholar
• Martin JL, Baxter RC. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem 1986;261:8754-60
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res 1995;6:223-9
   PubMedGoogle Scholar
• Cheetham TD, Holly JM, Clayton K, Cwyfan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet Med 1995;12:885-92
   PubMed Web of Science ®Google Scholar
• Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350:1199-204
   PubMed Web of Science ®Google Scholar
• Carroll PV, Umpleby M, Ward GS, et al. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 1997;46:1453-8
   PubMedGoogle Scholar
• Cheetham TD, Connors M, Clayton K, Watts A, Dunger DB. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I). Clin Endocrinol (Oxf) 1997;46:415-24
   PubMed Web of Science ®Google Scholar
• Quattrin T, Thrailkill K, Baker L, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997;20:374-80
   PubMed Web of Science ®Google Scholar
• Acerini CL, Harris DA, Matyka KA, et al. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 1998;47:1481-9
   PubMed Web of Science ®Google Scholar
• Crowne EC, Samra JS, Cheetham T, Watts A, Holly JM, Dunger DB. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 1998;47:31-8
   PubMed Web of Science ®Google Scholar
• Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999;22:585-92
   PubMed Web of Science ®Google Scholar
• Quattrin T, Thrailkill K, Baker L, Kuntze J, Compton P, Martha P. Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group. J Pediatr Endocrinol Metab 2001;14:267-77
   PubMed Web of Science ®Google Scholar
• Simpson HL, Jackson NC, Shojaee-Moradie F, et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 2004;89:425-32
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Keen H. Normoglycaemic re-entry and diabetic complications. Diabet Med 1984;1:85-7
   PubMedGoogle Scholar
• Grunwald JE, Riva CE, Martin DB, Quint AR, Epstein PA. Effect of an insulin-induced decrease in blood glucose on the human diabetic retinal circulation. Ophthalmology 1987;94:1614-20
   PubMed Web of Science ®Google Scholar
• Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993;36:282-91
   PubMed Web of Science ®Google Scholar
• Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992;90:2234-41
   PubMed Web of Science ®Google Scholar
• Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993;77:1563-8
   PubMed Web of Science ®Google Scholar
• Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994;43:369-74
   PubMed Web of Science ®Google Scholar
• Young SC, Clemmons DR. Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab 1994;78:609-14
   PubMed Web of Science ®Google Scholar
• Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996;45:91-100
   PubMed Web of Science ®Google Scholar
• Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 2000;85:3077-84
   PubMed Web of Science ®Google Scholar
• Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991;34:675-9
   PubMed Web of Science ®Google Scholar
• Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42:696-705
   PubMed Web of Science ®Google Scholar
• Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994;79:205-10
   PubMed Web of Science ®Google Scholar
• Zenobi PD, Glatz Y, Keller A, et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994;131:251-7
   PubMed Web of Science ®Google Scholar
• Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995;28 Suppl:S185-94
   PubMed Web of Science ®Google Scholar
• Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 1997;136:475-82
   PubMed Web of Science ®Google Scholar
• Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hubner C. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2006;2:395-407
   PubMedGoogle Scholar
• Woods KA, Dastot F, Preece MA, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-35
   PubMed Web of Science ®Google Scholar
• Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, editors. The IGF system. Totawa, NJ: Humana Press; 1999. p.739-70
   Google Scholar
• Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-10
   PubMed Web of Science ®Google Scholar
• Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997;82:629-33
   PubMed Web of Science ®Google Scholar
• Grahnen A, Kastrup K, Heinrich U, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 1993;82 Suppl 391:9-13
   PubMedGoogle Scholar
• Cotterill AM, Camacho-Hubner C, Holly JM, Savage MO. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome). Clin Endocrinol (Oxf) 1993;39:119-22
   PubMed Web of Science ®Google Scholar
• Backeljauw PF, Underwood LE. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001;86:1504-10
   PubMed Web of Science ®Google Scholar
• Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 1995;44:253-64
   PubMed Web of Science ®Google Scholar
• Adams S, Moore J, Chu S, et al. Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey. Prog Growth Factor Res 1995;6:347-56
   PubMedGoogle Scholar
• Bagi C, van der Meulen M, Brommage R, Rosen D, Sommer A. The effect of systemically administered rhIGF-I/IGFBP-3 complex on cortical bone strength and structure in ovariectomized rats. Bone 1995;16:559-65
   PubMed Web of Science ®Google Scholar
• Norman P. SomatoKine. Insmed. Curr Opin Investig Drugs 2003;4:466-71
   PubMedGoogle Scholar
• Sanders M, Moore J, Clemmons DR, Sommer A, Adams S. Safety pharmacokinetics and biological effects of intravenous administration of rhIGF-I/IGFBP-3 to healthy subjects. 79th Annual Meeting of the Endocrine Society; 1997 Jun 11-14; Minneapolis, MN
   Google Scholar
• Bagi CM, Brommage R, Deleon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res 1994;9:1301-12
   PubMed Web of Science ®Google Scholar
• Bagi CM, DeLeon E, Brommage R, Rosen D, Sommer A. Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Calcif Tissue Int 1995;57:40-6
   PubMed Web of Science ®Google Scholar
• Camacho-Hubner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006;91:1246-53
   PubMed Web of Science ®Google Scholar
• Camacho-Hubner C, Underwood LE, Yordam N, Yuksel B, Smith AV, Savage MO. Once daily rhIGF-I/rhIGFBP-3 treatment improves growth in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. 88th Annual Meeting of the Endocrine Society; 2006 Jun 24-28; Boston, MA
   Google Scholar
• Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518-24
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Moses AC, Sommer A, et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005;15:265-74
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Sleevi M, Allan G, Sommer A. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J Clin Endocrinol Metab 2007;92:2652-8
   PubMed Web of Science ®Google Scholar
• Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004;89:4634-41
   PubMed Web of Science ®Google Scholar
• Saukkonen T, Shojaee-Moradie F, Williams RM, et al. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 2006;55:2365-70
   PubMed Web of Science ®Google Scholar
• Williams RM, Yuen K, White D, et al. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates. Clin Endocrinol (Oxf) 2006;65:439-45
   PubMed Web of Science ®Google Scholar
• Baxter RC, Suikkari AM, Martin JL. Characterization of the binding defect in insulin-like growth factor binding protein-3 from pregnancy serum. Biochem J 1993;294:847-52
   PubMed Web of Science ®Google Scholar
• Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 2003;14:176-81
   PubMed Web of Science ®Google Scholar
• Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 2004;145:620-6
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Sleevi M, Busby WH Jr. Recombinant, nonglycosylated human insulin-like growth factor-binding protein-3 (IGFBP-3) is degraded preferentially after administration to type II diabetics, resulting in increased endogenous glycosylated IGFBP-3. J Clin Endocrinol Metab 2005;90:6561-8
   PubMed Web of Science ®Google Scholar
• McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol 2007;157 Suppl 1:S51-6
   PubMedGoogle Scholar
• Jeschke MG, Herndon DN, Barrow RE. Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats. Ann Surg 2000;231:408-16
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Bolder U, Chung DH, et al. Gut mucosal homeostasis and cellular mediators after severe thermal trauma and the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3. Endocrinology 2007;148:354-62
   PubMed Web of Science ®Google Scholar
• Debroy MA, Wolf SE, Zhang XJ, et al. Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma 1999;47:904-10
   PubMed Web of Science ®Google Scholar
• Herndon DN, Ramzy PI, DebRoy MA, et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999;229:713-20
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Barrow RE, Herndon DN. Insulin-like growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 2000;231:246-52
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Barrow RE, Suzuki F, Rai J, Benjamin D, Herndon DN. IGF-I/IGFBP-3 equilibrates ratios of pro- to anti-inflammatory cytokines, which are predictors for organ function in severely burned pediatric patients. Mol Med 2002;8:238-46
   PubMed Web of Science ®Google Scholar
• Spies M, Wolf SE, Barrow RE, Jeschke MG, Herndon DN. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002;30:83-8
   PubMed Web of Science ®Google Scholar
• Wolf SE, Woodside KJ, Ramirez RJ, Kobayashi M, Suzuki F, Herndon DN. Insulin-like growth factor-I/insulin-like growth factor binding protein-3 alters lymphocyte responsiveness following severe burn. J Surg Res 2004;117:255-61
   PubMed Web of Science ®Google Scholar
• Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002;87:1593-9
   PubMed Web of Science ®Google Scholar
• Iniguez G, Salazar T, Roman R, Avila A, Gunn RD, Cassorla F. Effects of the IGF-I/IGFBP-3 complex on GH and ghrelin nocturnal concentrations in low birth weight children. Clin Endocrinol (Oxf) 2006;65:687-92
   PubMed Web of Science ®Google Scholar
• Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128-34
   PubMed Web of Science ®Google Scholar
• Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994;43:369-74
   PubMed Web of Science ®Google Scholar
• Malozowski S, Stadel B. Risks and benefits of insulin-like growth factor. Ann Intern Med 1994;121:549
   PubMedGoogle Scholar